Late-stage clinical development of Chikungunya vaccines in endemic countries (CHIKV) and Controlled Human Infection Models for SARS-CoV2 and other beta coronaviruses (CHIM).
- Funded by European Commission
- Total publications:0 publications
Grant number: 101126531
Grant search
Key facts
Disease
COVID-19, UnspecifiedStart & end year
20232028Known Financial Commitments (USD)
$74,900,000Funder
European CommissionPrincipal Investigator
Breugelmans GabrielleResearch Location
NorwayLead Research Institution
COALITION FOR EPIDEMIC PREPAREDNESS INNOVATIONSResearch Priority Alignment
N/A
Research Category
Vaccines research, development and implementation
Research Subcategory
Phase 4 clinical trial
Special Interest Tags
N/A
Study Type
Clinical
Clinical Trial Details
Clinical Trial, Phase IV
Broad Policy Alignment
Pending
Age Group
Unspecified
Vulnerable Population
Pregnant womenOther
Occupations of Interest
Unspecified
Abstract
A Framework Partnership Agreement (FPA) between the Coalition for Epidemic Preparedness'ÄØInnovations (CEPI) and the European Union (EU) was signed in April 2019, to finance and coordinate the development of new medical countermeasures to prevent and contain infectious disease epidemics, which are of particular concern to low- and middle-income countries. As part of the FPA, a call for proposals (CfP) was launched jointly with the EU and supported the preclinical development of Rift Valley Fever Virus vaccines and the late-stage development of Chikungunya virus vaccines (CHIKV). While previous funding has led to the development of pre-licensure CHIK vaccines, in this current application we like to further advance our CHIK vaccine programme, and support CHIK vaccines that are near or have achieved regulatory licensure by supporting their clinical development into phase IV clinical trials to increase our understanding of the long-term safety, durability of protection, and effectiveness against virologically confirmed disease. Furthermore, we would like to expand the use indication by supporting clinical trials in vulnerable populations, including children, immunosuppressed and pregnant women.'ÄØ As part of this grant application, we also like to launch a CfP on Controlled Human Infection Models (CHIM). The overall objective of the CHIM proposal is to support research projects that increase knowledge in vaccine-induced mucosal immunity and advance the development of transmission-blocking vaccines against coronaviruses and other potential respiratory viral threats.'ÄØThe expected outcome of this CfP is to create a global network of experts conducting CHIM at a high level of consistency and reliability. This current grant application seeks to leverage 'Ǩ70M from Horizon Europe, which will be supplemented with 'Ǩ30M from CEPI making a pool of 'Ǩ100M. Awards will have a 36'Äì48-month duration and will be administered by the CEPI secretariat.